Pricing policy
Most-Favoured-Nation Drug Pricing
The executive order, the 17 deals, the tariffs, the three CMS models, the IRA, and what all of it does to European launches.
39 pages · 46 min read Read the report →
Careers & pay
The HEOR Salary & Career Report
What HEOR and market access professionals actually earn, by role, region and seniority, with the career paths that get people there.
2026 edition · 44 min read Read the report →Industry Reports.
The most comprehensive reviews of what truly matters in pharma.
- 100% free. You don't even need to give me your email 😉
- 100% independent. My own business, so my own opinion
- 100% unique. My voice and thoughts. Claude channels them 🪄
- 100% alive. Spot an error and email me, it gets fixed
- 100% transparent. Every claim referenced, so you can check it
Why free? Health economics is too important to lock behind a paywall. 🏰
EU HTA
In production
The Joint Clinical Assessment
Europe's single clinical dossier: what the JCA actually asks for, who it binds, and what it does to national HTA timelines.
Vote to see this first →
UK HTA
In production
NICE Technology Appraisals
Where appraisals actually land: timelines, outcomes, and what gets recommended on what evidence. Doubles as the snapshot behind the appraisal tracker I am building.
Vote to see this first →
AI
In production
Artificial Intelligence in HEOR
What AI genuinely does in health economics today, what it cannot do yet, and where the evidence for either claim comes from.
Vote to see this first →
Modelling
In production
The Health Economic Modelling Handbook
The complete reference: Excel, R and Python, from structure to validation. The decisions that matter, and the ones that do not.
Vote to see this first →
Global HTA
In production
Global HTA
The ten largest pharmaceutical markets side by side: timelines, willingness to pay, recent pricing reforms, and where the systems genuinely differ.
Vote to see this first →Beyond commentary.
The source of truth for market access & HEOR.
Most coverage of the pharmaceutical industry is very forgettable, poorly researched, and sadly, absent of authentic human thought. My reports cover a gap which other publications can't close: the complete, violently detailed picture on a single topic, traced back to executive orders, federal register notices, HTA guidance and published data, and written for the person who has to act on it rather than merely follow it.
I started with the MFN report because, even though seemingly every pharma analyst under the sun has written about it, I couldn't find one trusted source that puts all the pieces together. That's why I summarised everything you need to know about most-favoured-nation pricing for you in just under 40 pages, giving you a full list of the 68 primary sources in case you want to check my work. This includes the models, the timelines, the deals and the launch data, all in one place. Work of that shape usually comes with a hefty consulting price tag, or it does not get written at all because nobody foots the bill.
All my reports are free to read, right here, with no email form stopping you. Should you, however, feel GENEROUS (pun intended), I'm willing to send you the PDF version of these reports in exchange for your email. These reports are "living documents", meaning I'll do my best to revise them as the policy moves, with a changelog recording what changed and when, so what you read today is (hopefully!) not out of date next quarter. 🤞
I'm on a mission to build the world's leading knowledge platform for HEOR and market access, so that everyone working to improve access to medicines has the knowledge, tools and education they need to maximise their impact.
Everything I create serves the same mission. HEOR Fundamentals is the most comprehensive way to build your skills, and every enrolment helps me create more free resources for the global HEOR and market access community.
- HEOR Resources Tools, databases and guidelines worth knowing, in one place.
- The HEOR Roadmap The route into health economics, customisable to where you are now.
- The Pharma Glossary Every acronym in pricing, access and HEOR, defined properly.
- Pharma Radar One email every Tuesday to satisfy your market access needs.
- HEOR Fundamentals The guided course. First cohort starts 15 September 2026.
- The Discord community Where HEOR people actually ask each other things. Free to join.
- YouTube The world's largest HEOR channel on the platform.
- The Pharma Perspective The podcast. Long-form interviews with industry leaders.